Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04077424 · ClinicalTrials.gov registry record · Phase 4
Senescent Immunity in Elders and Vaccine Responses (SILVER)
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04077424 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT04077424, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
Interventions
- BIOLOGICAL Fluad
- BIOLOGICAL Fluzone-High Dose Quadrivalent
- BIOLOGICAL Flublock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2020-02-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04077424
The ClinicalTrials.gov registry entry for NCT04077424 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluad is the first listed.
NCT04077424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04077424 about?
NCT04077424 is a clinical study titled "Senescent Immunity in Elders and Vaccine Responses (SILVER)". To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
What is the current status of trial NCT04077424?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2019-10-21. Estimated completion is 2020-02-01.
What interventions are being tested in trial NCT04077424?
The interventions under investigation include: Fluad (BIOLOGICAL), Fluzone-High Dose Quadrivalent (BIOLOGICAL), Flublock (BIOLOGICAL).
Who is sponsoring clinical trial NCT04077424?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.